New drug combination for TB is tested in unique trialBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e5060 (Published 25 July 2012) Cite this as: BMJ 2012;345:e5060
- Zosia Kmietowicz
Researchers have found that a new combination of three drugs is as effective as the standard treatment for tuberculosis.
The novel combination, called PaMZ, is made up of PA-824, a brand new drug candidate for treatment of tuberculosis; moxifloxacin, an established antibiotic not yet approved for use in first line treatment of the disease; and pyrazinamide, which is often used in combination with established tuberculosis treatments.
Results from a small study involving just 80 patients found that, after two weeks of treatment, the mean early bactericidal activity (EBA, as measured by the daily rate of change of log10 colony forming units in sputum) of PaMZ (n=13; …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial